Home › Bids › Preclinical Proof of Concept Studies for Rare Diseases (R21

Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

Estimated Value: $275,000
Archived Healthcaregrant
This bid is closed — responses were due June 2, 2026. It is no longer accepting submissions. We keep closed bids on BidsNexus for reference: agencies often re-issue the same need, and past bids show what they buy and when.
See open bids like this one ↓ · Browse open bids →
Dec 6, 2024
Jun 2, 2026 12:00 AM
Healthcare
grant
...
AI Summary
This grant opportunity (RFA-TR-25-002) from the NIH funds preclinical proof of concept studies for rare diseases. Clinical trials are not allowed under this R21 mechanism.
Line Items
ItemQtyUnitEst. Unit PriceEst. TotalCategory
Preclinical Proof of Concept Study for Rare Disease 1 each $275,000.00 $275,000.00 Medical
Estimated Bid Value$275,000.00

Want the full details?

Sign up free to see the agency name and the original bid posting link. Pro adds contracting-officer contacts and AI response outlines.

Sign Up Free → Already have an account? Log in

Browse More Bids

Healthcare BidsGRANT BidsClosing Soon All Bids